Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 3:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 213 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Weight-based Protocol Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Development of an Adaptive Treatment for Weight Loss in People With Prediabetes

NCT04745572
View directory record Official record
Conditions
PreDiabetes, Obesity
Interventions
High Carbohydrate Diet, Reduced Carbohydrate Diet
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 27, 2026, 3:42 AM EDT
Terminated Phase 2 Interventional Results available

In-Home Evaluation of Episodic Administration of Palovarotene in Fibrodysplasia Ossificans Progressiva (FOP) Subjects

NCT02521792
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Palovarotene
Drug
Lead sponsor
Clementia Pharmaceuticals Inc.
Industry
Eligibility
6 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
San Francisco, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 27, 2026, 3:42 AM EDT
Completed Not applicable Interventional

Remotely Delivered Behavioral Weight Loss Using an Ad Libitum Plant-Based Diet Versus a Balanced Calorie Deficit Diet

NCT05337150
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Lifestyle Modification Intervention, Balanced Calorie Deficit Eating Plan, Ad Libitum Whole Food Plant-Based Eating Plan
Behavioral
Lead sponsor
Drexel University
Other
Eligibility
18 Years to 75 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Oct 27, 2026, 3:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

DASH Diet Intervention at Senior Centers

NCT03993808
View directory record Official record
Conditions
Hypertension
Interventions
Revision of congregate meal menus and recipes to align with parameters of DASH eating plan, On-site blood pressure monitoring, Home self blood pressure monitoring, Medical adherence education, Nutrition Education
Behavioral
Lead sponsor
Rockefeller University
Other
Eligibility
60 Years to 105 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 27, 2026, 3:42 AM EDT
Completed Phase 2 Interventional Results available

Islet Transplantation for Type 1 Diabetes

NCT00014911
View directory record Official record
Conditions
Diabetes Mellitus, Insulin-Dependent
Interventions
Islet Transplantation, Sirolimus, Tacrolimus, Daclizumab, Sulfamethoxazole, Ganciclovir, Trimethoprim, Pentamidine
Procedure · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
5
States / cities
Miami, Florida • Boston, Massachusetts • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 27, 2026, 3:42 AM EDT
Completed Phase 3 Interventional Results available

Bintrafusp Alfa Program Rollover Study

NCT05061823
View directory record Official record
Conditions
Lung Cancer, Cancer
Interventions
Bintrafusp alfa
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 27, 2026, 3:42 AM EDT
Completed Not applicable Interventional

Telehealth Delivered Physical Rehabilitation for an Ankle Sprain

NCT04520854
View directory record Official record
Conditions
Ankle Sprains, Telerehabilitation, Analgesic, Opioid, Analgesics, Non-narcotic, Anti-Inflammatory Agents, Non-Steroidal, Implementation Science, Acute Pain, Quality of Life
Interventions
Telehealth Protocol, Usual Care
Other
Lead sponsor
Kyle Kosik
Other
Eligibility
15 Years to 35 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 27, 2026, 3:42 AM EDT
Recruiting Phase 4 Interventional

Effect of Magnesium on Neuromonitoring

NCT06975072
View directory record Official record
Conditions
Spine, Pain, Spine Surgery, Spine Surgery With Neuromonitoring, Spine Surgery With Motor Evoked Potential Monitoring, Spine Fusion
Interventions
Magnesium sulfate administration
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 27, 2026, 3:42 AM EDT
Completed No phase listed Observational

Use of a Water Soluble Contrast-Based Protocol to Assist in the Management of Pediatric Adhesive Small Bowel Obstruction

NCT06101719
View directory record Official record
Conditions
Small Bowel Obstruction, Contrast Media Adverse Reaction
Interventions
Enteral contrast challenge
Diagnostic Test
Lead sponsor
Children's Hospital Colorado
Other
Eligibility
1 Year to 20 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • Oakland, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 27, 2026, 3:42 AM EDT
Recruiting Phase 3 Interventional

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

NCT03486873
View directory record Official record
Conditions
Solid Tumors, Hematologic Malignancies
Interventions
Pembrolizumab, Standard of Care (SOC), Lenvatinib, Olaparib, MK-4280, MK-4280A, Pembrolizumab (+) Berahyaluronidase alfa
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
3,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2043
U.S. locations
65
States / cities
Tucson, Arizona • Bakersfield, California • Fresno, California + 56 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 27, 2026, 3:42 AM EDT
Completed Phase 1 Interventional Results available

Biotin-RBC Transfusion in SCD

NCT04426591
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Biotin Labeled Red Blood Cells, Pathogen-reduced Biotin Labeled Red Blood Cells
Drug · Device
Lead sponsor
Marianne Yee
Other
Eligibility
2 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 27, 2026, 3:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study of Pulmonary Hypertension Peripheral Limitations

NCT05968859
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Healthy
Interventions
Aerobic Training, Leg Training
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 27, 2026, 3:42 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

NCT06379789
View directory record Official record
Conditions
Hemophilia B
Interventions
REGV131, LNP1265
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
2 Years and older · Male only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2047
U.S. locations
17
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 27, 2026, 3:42 AM EDT
Recruiting Not applicable Interventional

Flow and Grow - The Ideal Time to Wean CPAP Off In Extremely Low Birth Weight Infants

NCT06123143
View directory record Official record
Conditions
Neonatal Respiratory Failure
Interventions
Standardized/structured CPAP weaning protocol
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
Up to 30 Weeks
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
5
States / cities
Escondido, California • La Jolla, California • Murrieta, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 27, 2026, 3:42 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Application of High Resolution Diffusion-weighted MR Imaging Pulse Sequence in Head and Neck, and Prostate Cancers

NCT01535898
View directory record Official record
Conditions
Head and Neck Cancer, Prostate Cancer
Interventions
MRI scanner with sequence
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Oct 27, 2026, 3:42 AM EDT
Not yet recruiting Phase 2 Interventional

CSF-1R Inhibitor, Axatilimab, for Prevention of Acute and Chronic GVHD After HLA-Matched Related and Unrelated Donor Allogeneic Stem Cell Transplantation

NCT07808112
View directory record Official record
Conditions
Graft -Versus-host-disease
Interventions
Hematopoietic Cell Transplantation, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil (MMF), Axatilimab
Procedure · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 27, 2026, 3:42 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

D-Cycloserine Augmentation of Therapy for Pediatric Obsessive-Compulsive Disorder

NCT00864123
View directory record Official record
Conditions
Obsessive-compulsive Disorder
Interventions
Cognitive-behavioral therapy, D-cycloserine, Placebo pill
Behavioral · Drug
Lead sponsor
University of South Florida
Other
Eligibility
8 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Oct 17, 2012 · Synced Oct 27, 2026, 3:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Recovery of Bladder and Sexual Function After Spinal Cord Injury

NCT03036527
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Activity-based locomotor training, Activity-based stand training, Activity-based upper arm ergometry, Activity-based training + spinal epidural stimulation
Procedure
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Oct 27, 2026, 3:42 AM EDT
Terminated Early Phase 1 Interventional

Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers

NCT00882193
View directory record Official record
Conditions
Chronic Hepatitis C, Genotype 1, Relapse
Interventions
Betaine, Peginterferon alpha 2a, Ribavirin
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 27, 2026, 3:42 AM EDT
Recruiting Phase 1 Interventional

Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load

NCT06974877
View directory record Official record
Conditions
Cryopyrin-Associated Periodic Syndromes, Amyloidosis
Interventions
124I AT-01
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 120 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 27, 2026, 3:42 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Early Weight-Bearing After the Lapiplasty Mini-Incision Procedure (Mini3D)

NCT05082012
View directory record Official record
Conditions
Hallux Valgus, Bunion
Interventions
Treatment of Hallux Valgus
Device
Lead sponsor
Treace Medical Concepts, Inc.
Industry
Eligibility
14 Years to 58 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
10
States / cities
Decatur, Alabama • Hartselle, Alabama • Scottsdale, Arizona + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 27, 2026, 3:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Glycemic Control Using Insulin Levemir Versus Insulin NPH for Diabetes in Pregnancy

NCT01837680
View directory record Official record
Conditions
Diabetes, Gestational, Diabetes, Type 2
Interventions
Insulin
Drug
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years and older · Female only
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 27, 2026, 3:42 AM EDT
Completed Phase 4 Interventional Results available

Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial

NCT05590585
View directory record Official record
Conditions
Moderate-to-Severe Atopic Dermatitis, Atopic Eczema
Interventions
dupilumab, Topical emollient (moisturizer)
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
30
States / cities
Birmingham, Alabama • Montgomery, Alabama • Fremont, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 27, 2026, 3:42 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Circadian Time Restricted Eating

NCT05628012
View directory record Official record
Conditions
Circadian Rhythm, Cardiometabolic Health, Weight Loss, Cardiovascular Health, Time Restricted Feeding
Interventions
Circadian Based Time Restricted Eating
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 40 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Oct 27, 2026, 3:42 AM EDT